Alice T. Shaw, MD, PhD

Videos

Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non&ndash;small cell lung cancer.

Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer.

treatment of ALK-positive lung cancer > >

Articles

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer

Crizotinib Resistance in ALK-Positive Lung Cancer

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors and the treatment of ALK-positive lung cancer patients with crizotinib.

The treatment of these patients is more complicated now, with the advent of more potent ALK inhibitors

New ALK inhibitors are potent in patients both resistant and naive to crizotinib

At a large cancer center, the option exists to start crizotinib as standard therapy or consider a clinical trial with a next-generation ALK inhibitor

In the community setting, standard procedure would be to start a newly-diagnosed ALK-positive patient on crizotinib

Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.

The Advent of More Potent ALK Inhibitors

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses using crizotinib to treat patients with ALK-positive lung cancer.

Now that crizotinib is an FDA-approved agent, it is viewed as standard of care treatment for patients with ALK-positive lung cancer

A study showed that crizotinib is superior to chemotherapy in patients with ALK-positive lung cancer in the second-line setting

NCCN recommends testing patients with non-squamous lung cancer for

The results of a trial that compares crizotinib to frontline chemotherapy should be ready sometime next year

Alice T. Shaw, MD, PhD, discusses using crizotinib to treat patients with ALK-positive lung cancer.

Crizotinib in ALK-Positive Lung Cancer

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the results of a trial looking at LDK378 for patients with ALK+ crizotinib-resistant non-small cell lung cancer.

The results of the trial were remarkable, Shaw says, as nearly all patients in this population responded to LDK378.

In the case of EGFR-mutant lung cancer, there has been limited success once patients develop resistance to EGFR inhibitors. Because of this, it was unclear how successful ALK inhibitors would be in their respective space, but researchers were pleasantly surprised.

In the study, about 60% of patients responded, Shaw says. An additional 20-30% responded to treatment with LDK378, though formal criteria for a response was not met.

Nearly all crizotinib-resistant NSCLC patients responded to LDK378

EGFR-mutant lung cancer patients have seen limited success following resistance to EGFR inhibitors

About 60% of crizotinib-resistant patients responded to LDK378, with an additional 20-30% demonstrating some response

Alice T. Shaw, MD, PhD, discusses the results of a trial looking at LDK378 for patients with ALK+ crizotinib-resistant non-small cell lung cancer.

LDK378 in ALK+ Crizotinib-Resistant NSCLC Patients

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, describes a trial comparing crizotinib and chemotherapy in patients with advanced

Based on single-arm phase I and phase II trials, Shaw says, it was known that crizotinib was efficacious in this space. The primary endpoint of the trial, progression-free survival, was met.

Crizotinib showed superiority with regard to progression-free survival compared with chemotherapy: 7.7 months versus 3.0 months. In addition, Shaw points out, crizotinib significantly increased response rates, from 20% to 65%. These data confirm the efficacy of crizotinib in this space.

Crizotinib demonstrated superior progression-free survival compared with chemotherapy (7.7 months versus 3.0 months)

Response rates were 65% with crizotinib versus 20% with chemotherapy

Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.